Framycetin

Broad-spectrum aminoglycoside antibiotic. It is produced by bacteria of the genus Streptomyces. Framycetin has a "neomycin-like spectrum of action". Framycetin is used exclusively topically, often in combination with other antibiotics or in combination with glucocorticoids, and in bacterial infections of the skin and mucous membranes (e.g. conjunctiva). Framycetin is only available as a local therapy due to its high oto- and nephrotoxicity (powder, ointment 2%).

Framycetin has a bactericidal effect. The exact mechanism of action is not completely understood. However, Framycetin, like other aminoglycosides, appears to inhibit protein synthesis in bacteria by binding to ribosomal subunits. Framycetin is not active against fungi and viruses. Framycetin is also ineffective against Streptococcus pneumoniae and anaerobes.

Bacterial infectious diseases of the skin and mucous membranes. Framycetin is particularly suitable for skin infections caused by Pseudomonas aeruginosa and Proteus spp.

Cardiological UAW

• Cardiac arrhythmia
• Tachycardia

Immunological ADRs:

• Exanthema
• Contact allergic dermatitis
• Anaphylactic reactions

Neurological UAW:

• Hypotension
• Fake,

Gastrointestinal UAW:

• Nausea
• Vomiting

Hypersensitivity to aminoglycoside antibiotics

Renal insufficiency

Inner ear damage

pregnancy, lactation

Application for children and infants.

An ototoxic effect is also possible with topical application.

1. Abdou M A (1973) Sensitivity of Pseudomonas aeruginosa to gentamycin, carbenicillin and framycetin Pharmaceutical research 23: 785-791.
2. Ball AP et al (1975) Antibacterial Drugs today: II. Drugs 10: 81-111.
3. Finegold SM et al (1971) Susceptibility of gram-negative anaerobic bacilli to gentamicin and other aminoglycosides. J infect Dis 124: Suppl 56-58.